LETTER TO THE EDITOR
Open Access

Mutations in the D1 domain of von Willebrand factor impair their propeptide-dependent multimerization, intracellular trafficking and secretion

Jie Yin1, Zhenni Ma1, Jian Su1, Jiong-Wei Wang2, Xiaojuan Zhao1, Jing Ling3, Xia Bai1, Wanyan Ouyang1, Zhaoyue Wang1, Ziqiang Yu1 and Changgeng Ruan1*

Abstract
We identified three novel mutations (p.Gly39Arg, p.Lys157Glu, p.Cys379Gly) and one previously known mutation (p.Asp141Asn) in the von Willebrand factor propeptide from three von Willebrand disease patients. All four mutations impaired multimerization of von Willebrand factor, due to reduced oxidoreductase activity of isomeric propeptide. These mutations resulted in the endothelial reticulum retention and impaired basal and stimulated secretions of von Willebrand factor. Our results support that the mutations in the D1 domain lead to defective multimerization, intracellular trafficking, and secretion of von Willebrand factor and result in bleeding of patients.

Keywords: von Willebrand disease, VWF propeptide, VWF gene mutation, VWF multimerization, ER retention

Findings
Von Willebrand factor propeptide (VWFpp), composed of D1 and D2 domains, is necessary for the multimerization, intracellular trafficking, and secretion of the factor [1–3]. Few mutations in the D1 domain of VWFpp have been reported, and the pathogenic nature of these mutations remains largely unknown [4, 5]. We found three novel mutations (p.Gly39Arg, p.Lys157Glu, p.Cys379Gly) and one previously known mutation (p.Asp141Asn) in the VWFpp from three von Willebrand disease (VWD) patients (Additional file 1). The proband 1 (P1) and proband 2 (P2) were type 3 VWD, while the proband 3 (P3) was type 1 VWD [6]. The laboratory results of these patients and their family members are summarized in Table 1. P1 and P2 presented undetectable von Willebrand factor (VWF) multimer, and P3 exhibited light multimer pattern, compared to normal plasma (NP) (Additional file 2: Figure S1). All mutations are located in the D1 domain of VWFpp.

To determine whether and how these mutations impair VWF expression and function, we transiently transfected the human embryonic kidney 293 cells (HEK293) with wild type (WT) or VWF mutant constructs and analyzed VWF multimer (Fig. 1a,b). In the supernatant, the WT-VWF showed a full range of multimers similar to NP. Asp141Asn, Lys157Glu, and Cys379Gly mutants each exhibited different degrees of the loss of large- and medium-sized multimers. We also co-transfected Asp141Asn and Gly39Arg mutants and found that a partial VWF protein multimerization was readily detectable. When mutant and WT-VWF were co-transfected into HEK293 cells, the abnormal VWF multimers were all restored (Additional file 3: Figure S2). We examined cell lysates for VWF multimer and found that multimerization from all VWF mutations were inhibited in different levels as showed in the media. To determine the underlying mechanisms of defective VWF multimerization, we employed a previously established dimerization model using D1D2D3 fragment of VWF [7, 8]. In this model, the decreased dimerization of D1D2D3 indicates the reduced oxidoreductase of mutant VWFpp. Under the non-reducing condition (Fig. 1c), truncated WT (T-WT) VWF formed both D’D3 monomers and dimers in the

* Correspondence: cshcma@medmail.com.cn
1Collaborative Innovation Center of Hematology, MOH Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou 215006, China
Full list of author information is available at the end of the article

© 2015 Yin et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Phenotypic and genetic features of three unrelated VWD families

| Family | Members | VWF mutation | Genotype          | APTT ratio (sec) | PT ratio (sec) | TT ratio (sec) | VWF:Ag (IU/dL) | VWF:RCo (IU/dL) | FVIII:C (IU/dL) | BS |
|--------|---------|--------------|-------------------|------------------|----------------|----------------|----------------|----------------|----------------|-----|
| F1     | Proband P1 | G39R D141N | Compound heterozygous | 2.24             | 1.07           | 0.97           | 1.0            | 2.3            | 2.0            | 6   |
|        | Father P1F | D141N       | Heterozygous      | 1.09             | 1.15           | 1.24           | 48.4           | 50.2           | 73.5           | 0   |
|        | Mother P1M | G39R        | Heterozygous      | 1.12             | 1.05           | 0.91           | 30.3           | 36.4           | 50.6           | 1   |
| F2     | Proband P2 | K157E C1165R | Compound heterozygous | 1.95           | 1.04           | 0.89           | 3.0            | 2.1            | 3.0            | 6   |
|        | Father P2F | K157E       | Heterozygous      | 0.94             | 1.02           | 0.98           | 87.2           | 80.3           | 97.8           | 1   |
| F3     | Proband P3 | C379G       | Heterozygous      | 1.50             | 1.17           | 1.07           | 8.0            | 5.9            | 13.1           | 9   |
|        | Brother P3B | C379G       | Heterozygous      | 1.21             | 1.00           | 0.90           | 14.3           | 13.6           | 25.3           | 3   |
|        |          |             |                   |                  |                |                |                |                |                |     |

Normal range: APTT 0.82–1.18, PT 0.86–1.14, TT 0.80–1.20, VWF:Ag 50–160, VWF:RCo 50–120, FVIII:C 0–3 or 0–5

PT: prothrombin time, APTT: activated partial thromboplastin time, TT: thrombin time, VWF:Ag: von Willebrand antigen, VWF:RCo: von Willebrand factor ristocetin cofactor activity, FVIII:C factor VIII coagulant activity, BS: bleeding scores

Fig. 1 Defective multimerization of mutant VWF and reduced dimerization of mutant truncated VWF. a HEK293 cells were transiently transfected by equal WT or mutant full-length VWF plasmid. Seventy hours after transfection, the supernatant of cells were collected for multimer analysis. In order to detect whether the mutations have abnormal multimer pattern, we measured equal VWF antigen of the mutations, wild type, and NP. Lane 1 is the negative control of the mimic empty vector. Lanes 2–6 show the supernatant obtained from VWF mutant transfections and indicate decreases in high to medium-sized multimers to varying degrees. Exclusively, dimers formed with the Gly39Arg mutant (lane 2). The ability to form multimers was partly recovered by co-transfection of Gly39Arg and Asp141Asn (lane 4). b In the lysates of transfected cells, a similar decrease in the formation of VWF multimers was seen in the variants. However, WT-VWF exhibited a multimer pattern as observed for normal plasma. c HEK293 cells were transiently transfected by equal WT or mutant truncated VWF. In the media of transfected cells, dimerizations of truncated recombinant VWF were detected by Western blotting under the non-reducing condition. Lane 1 shows the empty pSecTag2/Hygro B vector. Dimers were absent in the Gly39Arg mutant (lane 2) while lanes 3–6 tapered in the dimer to different degrees. d In the supernatant of the transfected cells, the truncated VWF mutations and WT D1D2D3 fragment were examined under the reducing condition, and only D’D3 monomers were found.
supernatant. The dimerizations of truncated four variants (T-Gly39Arg, T-Asp141Asn, T-Lys157Glu, and T-Cys379Gly) were reduced, compared to that observed with T-WT. Co-transfection of the T-Gly39Arg and T-Asp141Asn resulted in a modest restoration of dimer formation compared to the single transfection of truncated Gly39Arg. This result indicates that the impaired multimerization is caused by decreased oxidoreductase activity of the isomeric propeptide. Under the reducing condition (Fig. 1d), D’D3 dimers were reduced to D’D3 monomers in both mutant and wild type D1D2D’D3 fragment.

The VWF antigen was measured in the conditioned media and cell lysates of the transiently transfected HEK293 cells (Additional file 4: Figure S3). The expressions of mutant Gly39Arg or Asp141Asn in the supernatant were significantly impaired, at the level of 2.8 ± 0.3 % to 2.5 ± 0.1 % of the WT. However, the expressions of mutant Lys157Glu or Cys379Gly product in the supernatant were less severely decreased at the levels of 26.0 ± 4.1 % and 22.4 ± 3.8 % of the WT. In co-transfection of Gly39Arg and Asp141Asn constructs, only 2.6 ± 0.1 % VWF was detectable in the supernatant, implying that both mutants do not mutually rescue each other from their defects. We also co-transfected the WT and each mutant (Gly39Arg, Asp141Asn, Lys157Glu, or Cys379Gly), and 59.3 ± 4.3 %, 57.3 ± 8.9 %, 86.6 ± 7.1 %, or 33.9 ± 12 % of WT were detected, respectively. This suggests that four mutants can be partially restored by the WT. In the cell lysates of single or co-transfected variants, the VWF levels did not change dramatically.

We found that the level of VWF antigen in the supernatant of HEK-293 cells expressing WT-VWF increased by 2.28-fold after phorbol 12-myristate-13-acetate (PMA) stimulation. However, cells expressing four mutations exhibited no significant changes in VWF antigen secretion upon PMA stimulation (Additional file 5: Figure S4).

By immunofluorescent staining of VWF proteins (Fig. 2a), we found that VWF formed green granules in cells. Only 37.8 ± 9.3 % WT-VWF was observed in the endoplasmic reticulum (ER), while 74.8 ± 2.5 % Gly39Arg. 

![Fig. 2 Mutant VWF is retained in the ER](image)

**a** HEK293 cells were transfected with plasmids expressing WT or mutant VWF and then stained for VWF (green channel, left panel). PDsRed2-ER Vector was also co-transfected into cells to delineate the endoplasmic reticulum (middle panel, red). The scale bar is 10 μm. The right panel shows the merged confocal images of the first two panels. **b** Bar graph represents VWF and the ER overlapping as a percentage of total VWF in cells (n = 3 independent experiments). All values are mean ± SD. ***p < 0.001 compared to WT (one-way ANOVA). After HEK293 cells were transiently transfected with WT or mutant full-length VWF, cell lysates were reduced and analyzed by Western blotting. The empty vector control is shown in lane 1. The bands of pro-VWF are predominant in the lysates of VWF mutant variants (lanes 2–5). Lane 6 shows both pro-VWF and mature VWF in the lysate of WT, and lane 7 shows only mature VWF in normal plasma.
84.6 ± 3.8 % Asp141Asn, 69.2 ± 3.6 % Lys157Glu, and 74.3 ± 1.8 % Cys379Gly mutants were detected in the ER (Fig. 2b). In the cell lysates, the bands of pro-VWF were predominant, and mature VWF was hardly detectable in the cells expressing Gly39Arg, Asp141Asn, Lys157Glu, and Cys379Gly, compared to that of WT-VWF (Fig. 2c). These results indicate that the mutant VWF are retained in the ER and fail to be transported to the Golgi, resulting in the decreased VWF secretion.

In summary, four mutations in the D1 domain of VWF impair the multimerization of VWF by directly downregulating the oxidoreductase of the propeptide, disrupt the transport of VWF from the ER to the Golgi, and inhibit the basal and regulated secretion of VWF. These defects contribute to the quantitative loss of VWF, leading to the bleeding diathesis of VWD patients.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JY and CR were the principal investigators and took primary responsibility for the paper. ZM, JS, JW, JL, and WH performed the laboratory work for this study. XZ, XB, ZW, and ZY recruited the patients. JY and JW wrote the paper. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the Jiangsu Provincial Special Program of Medical Science (BL2011002), Jiangsu Province’s Key Medical Center (ZX201102), Natural Science Foundation of Jiangsu Province (BK20140285), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The authors thank Prof. Lijun Xia, Oklahoma Medical Research Foundation and Prof. Xiaosheng Wu, Mayo Clinic, for critical reading and revisions.

Author details
1Collaborative Innovation Center of Hematology, MOH Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou 215006, China. 2Department of Surgery, National University of Singapore; Cardiovascular Research Institute (CRI), National University Heart Centre Singapore (NUHCS), National University Health System, Singapore 919992, Singapore. 3Department of Hematology and Oncology, Children’s Hospital of Soochow University, Suzhou 215003, China.

Received: 17 May 2015 Accepted: 3 June 2015
Published online: 20 June 2015

References
1. Journet AM, Saffaripour S, Wagner DD. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Thromb Haemost. 1993;70(6):1053–7.
2. Rosenberg JB, Habicher SL, Jozwiak MA, Vokac EA, Kroner PA, Fahs SA, et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood. 2002;100(5):1699–706.
3. Michaux G, Hewlett LJ, Messenger SL, Goodeve AC, Peake IR, Daly ME, et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003;102(7):2452–8. doi:10.1182/blood-2003-02-0599.
4. Barociani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, et al. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease. Haemophilia. 2008;14(3):549–55.
5. Michiels JJ, Gadsisseur A, van der Planken M, Schroyens W, Bemmezan Z. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains. Acta Haematol. 2009;121(2–3):111–8.
6. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–14.
7. Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem. 2004;279(48):49982–8.
8. Dang LT, Purvis AR, Huang RH, Westfield LA, Sadler JE. Phyllogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor. J Biol Chem. 2011;286(29):25763–9.